Adoption of immune checkpoint inhibitors (ICI) for unresectable locally advanced or metastatic urothelial carcinoma (u/mUC): A retrospective assessment of community oncology practices

被引：1
|
作者：
Aguilar, Kathleen M.
Grivas, Petros
Seal, Brian S.
Robert, Nicholas J.
Davies, Kalatu
Fleming, Mark T.
机构：
[1] Ontada, The Woodlands, TX USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[3] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[4] Ontada, Irving, TX USA
[5] US Oncol Res, Virginia Oncol Associates, Norfolk, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 28期
关键词：
D O I：
10.1200/JCO.2020.39.28_suppl.293
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
293
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).
    Talukder, Rafee
    Bakaloudi, Dimitra Rafailia
    Lin, Genevieve Ihsiu
    Enright, Tom
    Leary, Jacob Beck
    Makrakis, Dimitrios
    Tripathi, Nishita
    Agarwal, Neeraj
    Jindal, Tanya
    Koshkin, Vadim S.
    Brown, Jason R.
    Johnson, Jeffrey
    Zakharia, Yousef
    Park, Joseph J.
    Alva, Ajjai Shivaram
    Barrera, Rafael Morales
    Drakaki, Alexandra
    Barata, Pedro C.
    Khaki, Ali Raza
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma
    Takeshi Sano
    Ryoichi Saito
    Rihito Aizawa
    Tsubasa Watanabe
    Kaoru Murakami
    Yuki Kita
    Kimihiko Masui
    Takayuki Goto
    Takashi Mizowaki
    Takashi Kobayashi
    International Journal of Clinical Oncology, 2023, 28 : 1573 - 1584
  • [23] Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma
    Sano, Takeshi
    Saito, Ryoichi
    Aizawa, Rihito
    Watanabe, Tsubasa
    Murakami, Kaoru
    Kita, Yuki
    Masui, Kimihiko
    Goto, Takayuki
    Mizowaki, Takashi
    Kobayashi, Takashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (12) : 1573 - 1584
  • [24] Estimated impact of novel immune checkpoint inhibitors on reducing cancer mortality in patients with locally advanced or metastatic urothelial carcinoma in Russia.
    Alekseev, Boris
    Alekseev, Boris
    Avxentyev, Nikolay
    Makarova, Yuliya
    Andreiashkina, Irina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Approaches to immune checkpoint inhibitor (ICI) maintenance therapy in metastatic urothelial cancer (mUC): A qualitative analysis of oncology providers in the United States.
    Grivas, Petros
    Huber, Caroline
    Pawar, Vivek
    Roach, Meaghan
    May, Suepattra Grace
    Desai, Isha
    Chang, Jane
    Bharmal, Murtuza
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [26] Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Urol study.
    Bandini, Marco
    Fare, Elena
    Raggi, Daniele
    De Giorgi, Ugo
    Banna, Giuseppe Luigi
    Basso, Umberto
    Losanno, Tania
    Bersanelli, Melissa
    Buti, Sebastiano
    Santini, Daniele
    Mucciarini, Claudia
    Tucci, Marcello
    Tambaro, Rosa
    Farnesi, Azzurra
    Ficorella, Corrado
    Caffo, Orazio
    Naglieri, Emanuele
    Pederzoli, Filippo
    Pignata, Sandro
    Necchi, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] COMPARATIVE NARRATIVE REVIEW OF ONCOLOGY VALUE ASSESSMENT FRAMEWORKS: ENFORTUMAB VEDOTIN (EV) FOR TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC)
    Ortiz Nunez, A.
    Gonzalez Portela
    Zozaya, N.
    Meco, I
    VALUE IN HEALTH, 2023, 26 (12) : S365 - S365
  • [28] Immunological correlates of response and immune-mediated toxicity in checkpoint inhibitor (ICI)-treated metastatic urothelial carcinoma (mUC) patients (pts).
    Nizam, Amanda
    Tzeng, Alice
    Wei, Wei
    Rayman, Patricia A.
    Pavicic, Paul G.
    Makarov, Vladimir
    Juric, Ivan
    Alban, Tyler
    Swaidani, Shadi
    Sheng, Iris Yeong-Fung
    Gilligan, Timothy D.
    Gupta, Shilpa
    Diaz-Montero, C. Marcela
    Ornstein, Moshe Chaim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [29] Comprehensive metabolomic profiling of plasma from patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors (ICI) or platinum-based chemotherapy (PBC).
    El Zarif, Talal
    Adib, Elio
    Clish, Clary
    Shukla, Sachet A.
    Freeman, Dory
    Thomas, Jonathan
    Ravi, Praful
    Tuff, Martha
    McGregor, Bradley Alexander
    Mantia, Charlene
    Ravi, Arvind
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [30] BODY COMPOSITION AS A PREDICTIVE AND PROGNOSTIC BIOMARKER IN ADVANCED UROTHELIAL CARCINOMA (UC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI)
    Martini, Dylan
    Shabto, Julie
    Goyal, Subir
    Liu, Yuan
    Olsen, T. Anders
    Evans, Sean
    Magod, Benjamin
    Ravindranathan, Deepak
    Brown, Jacqueline
    Yantorni, Lauren
    Russler, Greta
    Caulfield, Sarah
    Goldman, Jamie
    Nazha, Bassel
    Joshi, Shreyas
    Kissick, Haydn
    Ogan, Kenneth
    Harris, Wayne
    Kucuk, Omer
    Carthon, Bradley
    Master, Viraj
    Bilen, Mehmet
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A27 - A29
12345